# A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

> **NCT05766501** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 641 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** DOR/ISL

## Key facts

- **NCT ID:** NCT05766501
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-17
- **Primary completion:** 2025-10-16
- **Final completion:** 2028-09-06
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05766501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05766501, "A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05766501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*